Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0268596 (EMA)
 2,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We present an anatomical-clinical analysis of ten cases of benign pleural fibroma. This tumour was discovered in a systematic fashion in 8 of the 10 cases and fortuitously in one. Recent radiological examinations enabled the diagnosis to be suspected. Computerised tomography most often precisely identified the pleural topography and imagery by nuclear magnetic resonance in one case visualised fibrous tissue (with a zone of low signals on the scale in T2). The final diagnosis was achieved at the same time as the treatment when an exploratory thoracotomy was performed. In all the cases there was a tumour composed of fusiform cells covered by normal epithelium coming from the viscera pleura 8 times out of 10. The ultrastructure examination and immunohistochemistry of the fusiform cells (Vimentin plus, EMA-, KL1-) allowed for a differentiation of these tumours of connective tissue origin from tumours of mesothelial origin. These analyses constitute an argument in favour of the fibroblastic origin of pleural fibromas.
Rev Mal Respir 1990
PMID:[Benign pleural fibroma. An anatomo-clinical study of 10 cases]. 169 92

The deleterious effects of asbestos exposure include benign and malignant pleuro-pulmonary lesions leading to considerable morbidity and mortality, underlying the necessity for improvement of early detection strategies. Pathological techniques (morphology and immunohistochemistry) remain the gold standard for diagnosis of asbestos related disorders, together with mineralogic studies and for determination of associated pathological processes. There are yet no reliable pathological tools able to survey and detect asbestos exposed patients which are non invasive, acceptable for the patients and obvious in directing efficient therapy. Three main conclusions are drawn: 1) Promising approach includes EMA immunostaining in the evaluation of suspicious mesothelial lesions; 2) P53, proteases immunostaining and K-Ras mutation analysis in early detection of bronchial preneoplasia; 3) sputum screening for specific tumor markers of transformation (hRNPA2/B1), or morphometric DNA quantification for the detection of subclinical bronchopulmonary carcinomas. These recent developments are the first step of a long road to routine detection of these lesions.
Rev Mal Respir 1999 Dec
PMID:[Anatomopathological tools for screening and medical surveillance of people exposed to asbestos]. 1089 45